IN THE UNITED STATES PATENT AND TRADEMARK OFFICE APPLICATION AND FEE TRANSMITTAL

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



Sir:

This is a request for filing a \(\subseteq 0	continuation patent application	divisional patent application
---	---------------------------------	-------------------------------

under 37 C.F.R. §1.53(b), of pending prior application Serial No. 09/912,157 filed on July 24, 2001 entitled HUMAN CYTOKINE RECEPTOR, incorporated herein by reference.

Prior Examiner: F. Hamud Prior Art Unit: 1647

Enclosed are the following papers:

Dilei	oscu are t	ne ronowing papers.
\boxtimes	85	pages of specification
\boxtimes	2	sheets of Declaration and Power of Attorney
		sheets of Figures
\boxtimes	24	pages of sequence listing
\boxtimes	4	pages Information Disclosure Statement and PTO-1449
\boxtimes	1	page Letter Regarding Sequence Listing
	1	page Letter Identifying Changes
\boxtimes	1	page Petition and Fee for Extension of Time
		A Preliminary Amendment is enclosed.
\boxtimes	1	page Associate Power of Attorney
	The second	

- The prior application is assigned of record to ZymoGenetics, Inc.
- Address all future communications to Brian J. Walsh, Patent Department, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, Washington 98102.
- Enclosed is a ASCII Computer Disk Sequence pursuant to 37 C.F.R. 1.821(f). It is believed that the content of the paper sequence listing and the computer readable sequence listing are the same.

CALCULATION OF APPLICATION FEE

Claim Type	No. Filed	Less	Extra	Extra Rate	Fee
Total	14	-20	0	\$9.00	\$000.00
Independent	3	-3	0	\$43.00	\$000.00
		Basic Fee	•		\$385.00
		Multiple I	Dependency Fe	e	\$000.00
		If Applica	ble (\$145.00)		\$000.00
		Total Fili	ng Fee		\$385.00

Applic	ants claim small entity status. Please charge LymoGenetics, Inc., Deposit Account No. 26-0290 as
follows	
\boxtimes	Filing fee, estimated to be \$385
	Assignment recording fee
\boxtimes	Any additional fees associated with this paper or during the pendency of this application.
	The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37
	C.F.R. 1.311(b).
A copy	of these sheets is enclosed.

Respectfully submitted,

Brian J. Walsh Registration No. 45,543

File No.: 00-49C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re: U.S. Patent Application for

HUMAN CYTOKINE RECEPTOR

Applicants: Scott R. Presnell, Rolf E. Kuestner, Zeren Gao

Sir:

Express Mail Label No. EV 331816137US Date of Deposit November 19, 2003

I hereby certify that the following attached paper(s) or fee

- 1. Return Post card
- 2. Application And Fee Transmittal (in duplicate)
- 3. Patent Application (85 pages)
- 4. Information Disclosure Statement and PTO-1449 (4 pages)
- 5. Copy of Executed Declaration and Power of Attorney
- 6. Sequence Listing (24 pages)
- 7. Letter Regarding Sequence Listing
- 8. Letter Identifying Changes
- 9. Petition and Fee for Extension of Time for USSN 09/912,157 (in duplicate)
- 10. Associate Power of Attorney

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kim M. Goplen

ZymoGenetics, Inc. 1201 Eastlake Avenue East Seattle, WA 98102 (206) 442-6600

Express Mail Label No. EV 331816137US

PATENT APPLICATION File No.: 00-49C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Scott R. Presnell, Rolf E. Kuestner, Zeren Gao

For:

HUMAN CYTOKINE RECEPTOR

Filed:

November 19, 2003

LETTER IDENTIFYING CHANGES

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The specification submitted herewith has been amended from the parent application as follows:

Page 1 has been amended to include a Cross-Reference to Related Applications.

The instant continuing patent application includes a new set of claims. The claims are directed only to subject matter disclosed in the prior application.

No new matter has been added.

Respectfully submitted,

Brian J. Walsh

Registration No. 45,543